pioneer 9 semaglutide Dose-response, efficacy, and safety of oral monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial Efficacy and safety of oral

The 2nd GLP-1-Based Therapeutics Summit returns to tackle the challenges in best-in-class GLP-1 development and indication expansion with new clinical data, new preclinical data, and 18+ expert speakers including Eli Lily, Regeneron, Roche, Novo Nordisk, Fractyl Health and more at the forefront of the field

Find safe, over-the-counter supplements to support your GLP-1 journey

A qualified provider should guide any GI interventions to avoid complications

Chernoff Cosmetic Surgery offers expert solutions

Lower GLP-1 doses for athletes: less appetite suppression, fewer side effects, maintained fueling ability, still losing fat